Company profile
Capricor Therapeutics, Inc.
NASDAQ: CAPR · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
57CFH 68DQ 62GM 5SS 73
v0.1 · 65/100 weight · provisional
↑ Altman-Z, balance-sheet leverage · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$105.0M
Employees
231
as of 2026-08-10
Market cap
$235.2M
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$105.0M-$105.0M2025
Operating income-$108.1M-$108.1M2025
Total assets$355.9M$355.9M2025
Liabilities$50.2M$50.2M2025
Equity$305.8M$305.8M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Capricor Therapeutics, Inc.’s revenue?
Capricor Therapeutics, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Fulcrum Therapeutics, Inc.58CALX Oncology Holdings Inc.37DCytoDyn Inc.30DMinerva Neurosciences, Inc.37DEupraxia Pharmaceuticals Inc.42DCorbus Pharmaceuticals Holdings, Inc.46DNeighbors
San Diego →Key facts
CEOLinda Marbán
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: CAPR
Employees231
IPO date2007-02-13
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.